These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 12774574)
41. Thermoplastic elastomers in medical applications. Radley H Med Device Technol; 2003 May; 14(4):38-40. PubMed ID: 12774579 [TBL] [Abstract][Full Text] [Related]
42. The patentability of human embryonic stem cells in Europe. Porter G; Denning C; Plomer A; Sinden J; Torremans P Nat Biotechnol; 2006 Jun; 24(6):653-5. PubMed ID: 16763591 [TBL] [Abstract][Full Text] [Related]
43. Biotechnology patenting policy in the European Union--as exemplified by the development in Germany. Schrell A; Bauser H; Brunner H Adv Biochem Eng Biotechnol; 2007; 107():13-39. PubMed ID: 17522818 [TBL] [Abstract][Full Text] [Related]
48. Converging medical technologies and standards. Moore R Med Device Technol; 2004; 15(1):32. PubMed ID: 14994637 [No Abstract] [Full Text] [Related]
49. Much ado about gene patents: the role of foreseeability. Gulliford MJ Seton Hall Law Rev; 2004; 34(2):711-45. PubMed ID: 15115032 [No Abstract] [Full Text] [Related]
51. Patent protection for stem cell procedures under the law of the European Union. Spranger TM Med Etika Bioet; 2003; 10(1-2):4-8. PubMed ID: 16294439 [TBL] [Abstract][Full Text] [Related]
52. A brief guide to understanding patentability and the meaning of patents. Elliott GC Acad Med; 2002 Dec; 77(12 Pt 2):1309-14. PubMed ID: 12480641 [TBL] [Abstract][Full Text] [Related]
53. Time waits for no man: deciding when to file a patent application in Europe. White NL Nat Biotechnol; 2007 Jun; 25(6):639-41. PubMed ID: 17557096 [No Abstract] [Full Text] [Related]
54. Patents, patients, and public policy: an incomplete intersection at 35 U.S.C. Section 287(c). Ho CM Univ Calif Davis Law Rev; 2000; 33(3):601-75. PubMed ID: 16389678 [No Abstract] [Full Text] [Related]
55. [The generic Research and Development possibilities after Hungary accessed th European Patent Convention]. Kelen A; Angyal N; Máthé Z; Bódis A; Hódi K Acta Pharm Hung; 2003; 73(2):123-9. PubMed ID: 14702693 [TBL] [Abstract][Full Text] [Related]
56. The case for patenting medical procedures. Garris JJ Am J Law Med; 1996; 22(1):85-108. PubMed ID: 8819597 [No Abstract] [Full Text] [Related]
57. Australia experiments with 'experimental use' exemption. McBratney A; Nielsen K; McMillan F Nat Biotechnol; 2004 Aug; 22(8):1023-5. PubMed ID: 15286651 [TBL] [Abstract][Full Text] [Related]
58. Innovation and intellectual property rights in systems biology. Allarakhia M; Wensley A Nat Biotechnol; 2005 Dec; 23(12):1485-8. PubMed ID: 16333286 [TBL] [Abstract][Full Text] [Related]
59. Ethical questions to ponder in the European stem cell patent debate. Curley D; Sharples A J Biolaw Bus; 2006; 9(3):12-6. PubMed ID: 17152135 [TBL] [Abstract][Full Text] [Related]
60. Different rules, different results: patent litigation after In re Baxter. Vogel BJ; Roberg-Perez SE Pharm Pat Anal; 2013 May; 2(3):295-7. PubMed ID: 24237055 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]